Location:
Marriott Marquis Washington, DC
901 Massachusetts Ave NW
Washington, DC 20001
Hotel Phone: (202) 824-9200
Meeting Room:
Independence A-E (Meeting Level 4)
Schedule (EST):
5:30 AM – 6:00 AM
Registration and Breakfast Buffet
6:00 AM – 7:30 AM
Educational Program
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.
Faculty:
Bernadette Cuello, MSN, NP-C, AOCNP
Nurse Practitioner, Outpatient Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York
Eytan M Stein, MD
Hematologist and Medical Oncologist
Assistant Attending Physician
Leukemia Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Wendy Stock, MD
Anjuli Seth Nayak Professor of Leukemia Research
Director, Leukemia Program
The University of Chicago Medicine
Chicago, Illinois
Lauren Ziskind, APN, NP-C, OCN
Nurse Practitioner, Adult Leukemia Program
The University of Chicago
Chicago, Illinois
Moderator:
Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a symposium supported by AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Astellas Pharma Global Development Inc, Celgene Corporation and Jazz Pharmaceuticals Inc during the Oncology Nursing Society’s (ONS) 43rd Annual Congress, May 16-20, 2018 in Washington, DC. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of acute leukemias.
Learning Objectives:
Upon completion of this activity, participants should be able to:
- Assess available research evidence with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for appropriate patients with acute myelogenous leukemia (AML).
- Develop an understanding of the mechanism of action, available data and current and potential role of available and investigational IDH1/2 inhibitors for patients with relapsed/refractory AML and IDH1/2 mutations.
- Recognize the recent FDA approval of CPX-351 for newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, and discern how this agent can be optimally integrated into nonresearch care algorithms for these patients.
- Apply the results of clinical research on existing (CAR-T therapy, blinatumomab, inotuzumab ozogamicin) and emerging agents to optimize the clinical and supportive care of patients with newly diagnosed and recurrent acute lymphocytic leukemia.
- Educate patients about the side effects associated with existing and recently approved therapies, and provide preventive strategies to reduce or ameliorate these toxicities.
Accreditation Statement:
Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
Credit Designation Statements:
This educational activity for 1.5 contact hours is provided by RTP.
This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.
To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.
Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information:
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE credit to utilize this program for ONCC certification or renewal.
http://www.ResearchToPractice.com/Meetings/ONS2018/ILNA
Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.
Content Validation and Disclosures:
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
RTP staff and external reviewers — The scientific staff, planners and managers for RTP have no relevant conflicts of interest to disclose.
Supporters:
This activity is supported by educational grants from AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Astellas Pharma Global Development Inc, Celgene Corporation and Jazz Pharmaceuticals Inc.
Marriott Marquis Washington, DC
901 Massachusetts Ave NW
Washington, DC 20001
Hotel Phone: (202) 824-9200
Meeting Room:
Independence A-E (Meeting Level 4)
The Marriott Marquis Washington, DC is the headquarters hotel for the 2018 ONS Congress and provides direct access to the Walter E Washington Convention Center via an underground concourse.
Thank you for your interest in our CNE symposia series. At this time, online preregistration is closed for PART 5 — Acute Leukemias. Onsite registration will be open starting at 5:30 AM (ET) on Friday, May 18th.
If you are interested in standing by for seating (day of the program), please visit our onsite registration desk located outside Independence A-E, Ballroom (Meeting Level 4) at the Marriott Marquis Washington, DC (901 Massachusetts Ave NW, Washington, DC 20001). You may arrive up to 45 minutes before the program start time and receive a standby ticket.
If seats become available for the program, we will accept standby registration on a first come, first served basis. Please note, onsite registration does not guarantee participation in the session or meal service. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.